{
    "clinical_study": {
        "@rank": "161514", 
        "arm_group": [
            {
                "arm_group_label": "Treatment regimn 1", 
                "arm_group_type": "Experimental", 
                "description": "150 mg Fenobam Orally - once"
            }, 
            {
                "arm_group_label": "Treatment Regimen 2", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo orally - once"
            }
        ], 
        "brief_summary": {
            "textblock": "Our goal is to demonstrate that healthy volunteers treated with fenobam will develop a\n      significantly reduced area of cutaneous hyperalgesia compared to volunteers treated with\n      placebo, after exposure to the heat/capsaicin model of cutaneous sensitization. Additionally\n      we are going to assess changes in mood/affect and cognitive function of subjects following\n      administration of fenobam and after cutaneous sensitization compared to baseline."
        }, 
        "brief_title": "Fenobam on Heat/Capsaicin Induced Hyperalgesia in Healthy Volunteers", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hyperalgesia, Experimental", 
            "Allodynia, Experimental"
        ], 
        "condition_browse": {
            "mesh_term": "Hyperalgesia"
        }, 
        "detailed_description": {
            "textblock": "All subjects will receive a topical dose of capsaicin cream 0.1%(Capzasin-HP) to the forearm\n      at the start of the study visit. The order of the 2 treatment regimens indicated below will\n      be randomized and blinded to subjects and researchers.\n\n      Treatment Regimen 1:  Fenobam  [1-(3-chlorophenyl)-3-(1-methyl-4-oxo-2-imidazolidinylidine)\n      urea hydrate]: administration of one 150 mg gelatin capsule.\n\n      Treatment Regimen 2: Placebo (lactose monohydrate): administration of one 150 mg gelatin\n      capsule."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. 18-50 year old\n\n          2. Good general health with no remarkable medical conditions (e.g.  liver, kidney,\n             heart, or lung failure)\n\n          3. BMI between 20-33\n\n          4. Willing to comply with study guidelines as outlined in protocol [including: women of\n             childbearing age must be willing to use a double-barrier method (e.g. oral\n             contraception and condom) for contraception during participation in the study]\n\n          5. Willing to provide informed consent\n\n        Exclusion Criteria:\n\n          1. Anatomical malformation of upper extremities\n\n          2. Status post recent trauma or chronic lesions on either forearm\n\n          3. Medication use (includes vitamin, herbal, dietary and mineral supplements and\n             grapefruit products during or within 14 days prior to study participation; excludes\n             contraceptives)\n\n          4. History of allergy or intolerance to capsaicin\n\n          5. History of multiple drug allergies\n\n          6. History of addiction to drugs or alcohol (prior or present addiction or treatment for\n             addiction)\n\n          7. History of chronic pain syndromes\n\n          8. Pregnant and nursing females\n\n          9. Smokers"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01981395", 
            "org_study_id": "201311094"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment regimn 1", 
                "description": "Fenobam 150 mg will be administered and subjects will be monitored for up to 8 hours.  During the study day questionnaires will be administered, blood will be drawn a testing site will be marked and pain testing and heat/capsaicin sensitization will be measured.", 
                "intervention_name": "Fenobam", 
                "intervention_type": "Drug", 
                "other_name": "[1-(3-chlorophenyl)-3-(1-methyl-4-oxo-2-imidazolidinylidine) urea hydrate]"
            }, 
            {
                "arm_group_label": "Treatment Regimen 2", 
                "description": "A placebo will be administered and subjects will be monitored for up to 8 hours.  During the study day questionnaires will be administered, blood will be drawn a testing site will be marked and pain testing and heat/capsaicin sensitization will be measured.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Lactose monohydrate"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Capsaicin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "fenobam", 
            "heat", 
            "capsaicin", 
            "hyperalgesia", 
            "allodynia", 
            "mood", 
            "cognitive function"
        ], 
        "lastchanged_date": "March 31, 2014", 
        "location": {
            "contact": {
                "email": "cavallol@wustl.edu", 
                "last_name": "Laura Cavallone, MD", 
                "phone": "314-286-1045"
            }, 
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University School of Medicine"
            }, 
            "investigator": {
                "last_name": "Laura F Cavallone, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double Blind, Randomized, Placebo Controlled, Crossover Study to Investigate the Anti-hyperalgesic Efficacy of a Single Dose of Fenobam on Heat/Capsaicin Induced Cutaneous Hyperalgesia in Adult Healthy Volunteers.", 
        "overall_contact": {
            "email": "freyk@anest.wustl.edu", 
            "last_name": "Karen Frey", 
            "phone": "314-454-5980"
        }, 
        "overall_contact_backup": {
            "email": "bloodj@anest.wustl.edu", 
            "last_name": "Jane Blood, RN", 
            "phone": "314-747-5531"
        }, 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "Laura F Cavallone, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "size of the area of hyperalgesia and allodynia around the area sensitized by heat/capsaicin as quantified by cutaneous stimulation with foam brush strokes and a von Frey filament requiring 26 g of bending force.", 
            "measure": "Suppression of the development of cutaneous hyperalgesia and allodynia around the area treated with heat/capsaicin.", 
            "safety_issue": "No", 
            "time_frame": "During approximately 7 hours of consecutive assessments"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01981395"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Washington University", 
            "investigator_full_name": "Laura Cavallone", 
            "investigator_title": "Assistant Professor of Anesthesiology", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Visual Analog Scale (VAS) rating of pain perception at 1 min 45\u00b0C heat stimulation on normal  skin.", 
                "measure": "Evaluation of nociception after drug administration as evaluated by prolonged (1 min) thermal stimulation on normal (untreated) skin.", 
                "safety_issue": "No", 
                "time_frame": "During approximately 7 hours of consecutive assessments"
            }, 
            {
                "description": "lowest temperature perceived as painful with stimulation starting at 32\u00b0C and with a safety cut-off at 52\u00b0C.", 
                "measure": "Assessment of Heat Pain Detection Thresholds (HPDT) in normal and sensitized skin pre and post treatment with fenobam.", 
                "safety_issue": "No", 
                "time_frame": "During approximately 7 hours of consecutive assessments"
            }, 
            {
                "description": "Determined by subjects' monitoring during treatment sessions and follow up at 1 day and 1 week after treatment with drug.", 
                "measure": "Absence of significant side effects", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }, 
            {
                "description": "As determined by evaluation of the subjects by combined brief Positive And Negative Affect Scale/Brief State Anxiety Measure (PANAS/BSAM)", 
                "measure": "Assessment of significant change in mood/affect", 
                "safety_issue": "No", 
                "time_frame": "During approximately 6  hours of consecutive assessments"
            }, 
            {
                "description": "As determined by evaluation of the Letter and Number Sequencing (LNS) assessment", 
                "measure": "Assessment of significant change in cognitive function", 
                "safety_issue": "Yes", 
                "time_frame": "During approximately 6  hours of consecutive assessments"
            }
        ], 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Laura Cavallone", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}